Biotricity Strengthens its Foundation for Growth, Achieves Lower Cost of Sales, Expanding Margins of 73% and Increased Device Sales, for Third Quarter of Fiscal Year 2024

Stock Information for Biotricity Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Biotricity Inc.

Biotricity's Path Towards Breakeven Accelerated by Latest Diagnostic Product, Biotres Pro, Garnering Rapid Interest from Existing and New Customers
Biotricity Launches Major Cardiac Monitoring Pilot Program in a Hospital System Comprised of 9 Hospitals and 10 Clinics
Biotricity Launches Cardiac Monitoring Pilot Program with Major Hospital Network
Biotricity Announces a Strategic Partnership for Cardiac Screenings in Patients with Co-Morbidities
LOBO EV and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Biotricity Accelerates Market Access by Partnering with Third Major Group Purchasing Organization, Expanding Market Reach to 90% of U.S. Hospitals
Biotricity Partners with Health Aid Africa to Provide Complementary Heart Health Screenings at Allegiant Stadium Concert
Biotricity Unveils that Improved Margins Resulted from Latest Advancements to its Proprietary Cardiac AI Cloud Platform and Announces Plans for Continued Expansion of its Cardiac AI Cloud

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.